STOCK TITAN

Alaunos Therapeutics Inc - TCRT STOCK NEWS

Welcome to our dedicated news page for Alaunos Therapeutics (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alaunos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alaunos Therapeutics's position in the market.

Rhea-AI Summary
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) announced an 87% disease control rate in the TCR-T Library Phase 1/2 trial for metastatic solid tumors. The trial showed well-tolerated TCR-T cell therapy with no dose-limiting toxicities. The company's hunTR® platform discovered TCRs recognizing driver mutations, including KRAS and TP53. Alaunos is exploring strategic alternatives to extend cash runway and has reduced its workforce by 80%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
-
Rhea-AI Summary
Alaunos Therapeutics to wind down TCR-T Library trial and focus on hunTR® platform, reducing workforce by 60%
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-64.1%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.95%
Tags
none
Rhea-AI Summary
Alaunos Therapeutics, Inc. announced that they will present early translational data from their ongoing TCR-T Library Phase 1/2 trial at the ASCO Annual Meeting. The data highlights the effectiveness and safety of their non-viral TCR-T cell therapy in treating solid tumors with high-frequency driver mutations. Two out of three patients showed anti-tumor activity, with one achieving a partial response and another achieving stable disease. TCR persistence and tumor infiltration were observed in patients, indicating the potential of this therapy. More data will be provided in the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
Alaunos Therapeutics Inc

Nasdaq:TCRT

TCRT Rankings

TCRT Stock Data

25.78M
13.34M
4.39%
17.14%
9.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Houston

About TCRT

ziopharm oncology, inc., is a biopharmaceutical company focused on the discovery and development of new cancer therapies. we are applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.